Agios Pharma Won't Advance Tebapivat for Lower-Risk Myelodysplastic Syndromes

Dow Jones05-29

By Chris Wack

Agios Pharmaceuticals said it won't advance its tebapivat, an oral pyruvate kinase activator, in lower-risk myelodysplastic syndromes, after a Phase 2b trial didn't meet the company's predefined threshold to support further development in this indication.

The commercial-stage biopharmaceutical company said the 24-week dose-finding trial evaluated once-daily tebapivat in 65 patients with LR-MDS and anemia.

The primary endpoint was transfusion independence, defined as eight consecutive weeks without a transfusion during the 24-week treatment period. Agios said tebapivat demonstrated evidence of biological activity, but that it didn't see clinical benefit in a sufficient proportion of patients or subgroup of patients to meet the company's predefined threshold for advancement.

Tebapivat was well tolerated across all dose levels, with no new safety signals identified.

Agios said tebapivat is also being evaluated in a Phase 2 trial for the treatment of sickle cell disease, with top-line data anticipated in the second half of 2026.

Shares were down 5.5% to $28.75 in premarket trading.

Write to Chris Wack at chris.wack@wsj.com

(END) Dow Jones Newswires

May 29, 2026 07:30 ET (11:30 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2639242486?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-29 19:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2639242486","market":"us","top_or_hot":-1,"title":"Agios Pharma Won't Advance Tebapivat for Lower-Risk Myelodysplastic Syndromes","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Chris Wack \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Agios Pharmaceuticals said it won't advance its tebapivat, an oral pyruvate kinase activator, in lower-risk myelodysplastic syndromes, after a Phase 2b trial didn't meet the company's predefined threshold to support further development in this indication. \n</p>\n<p>\n  The commercial-stage biopharmaceutical company said the 24-week dose-finding trial evaluated once-daily tebapivat in 65 patients with LR-MDS and anemia. \n</p>\n<p>\n  The primary endpoint was transfusion independence, defined as eight consecutive weeks without a transfusion during the 24-week treatment period. Agios said tebapivat demonstrated evidence of biological activity, but that it didn't see clinical benefit in a sufficient proportion of patients or subgroup of patients to meet the company's predefined threshold for advancement. \n</p>\n<p>\n  Tebapivat was well tolerated across all dose levels, with no new safety signals identified. \n</p>\n<p>\n  Agios said tebapivat is also being evaluated in a Phase 2 trial for the treatment of sickle cell disease, with top-line data anticipated in the second half of 2026. \n</p>\n<p>\n  Shares were down 5.5% to $28.75 in premarket trading. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Chris Wack at chris.wack@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 29, 2026 07:30 ET (11:30 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Agios Pharma Won't Advance Tebapivat for Lower-Risk Myelodysplastic Syndromes</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAgios Pharma Won't Advance Tebapivat for Lower-Risk Myelodysplastic Syndromes\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-05-29 19:30</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Chris Wack \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Agios Pharmaceuticals said it won't advance its tebapivat, an oral pyruvate kinase activator, in lower-risk myelodysplastic syndromes, after a Phase 2b trial didn't meet the company's predefined threshold to support further development in this indication. \n</p>\n<p>\n  The commercial-stage biopharmaceutical company said the 24-week dose-finding trial evaluated once-daily tebapivat in 65 patients with LR-MDS and anemia. \n</p>\n<p>\n  The primary endpoint was transfusion independence, defined as eight consecutive weeks without a transfusion during the 24-week treatment period. Agios said tebapivat demonstrated evidence of biological activity, but that it didn't see clinical benefit in a sufficient proportion of patients or subgroup of patients to meet the company's predefined threshold for advancement. \n</p>\n<p>\n  Tebapivat was well tolerated across all dose levels, with no new safety signals identified. \n</p>\n<p>\n  Agios said tebapivat is also being evaluated in a Phase 2 trial for the treatment of sickle cell disease, with top-line data anticipated in the second half of 2026. \n</p>\n<p>\n  Shares were down 5.5% to $28.75 in premarket trading. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Chris Wack at chris.wack@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 29, 2026 07:30 ET (11:30 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AGIO","symbol_name":"Agios Pharmaceuticals, Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2639242486","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2639242486","pubTimestamp":1780054200,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Agios Pharmaceuticals said it won't advance its tebapivat, an oral pyruvate kinase activator, in lower-risk myelodysplastic syndromes, after a Phase 2b trial didn't meet the company's predefined threshold to support further development in this indication.The commercial-stage biopharmaceutical company said the 24-week dose-finding trial evaluated once-daily tebapivat in 65 patients with LR-MDS and anemia.The primary endpoint was transfusion independence, defined as eight consecutive weeks without a transfusion during the 24-week treatment period. Agios said tebapivat demonstrated evidence of biological activity, but that it didn't see clinical benefit in a sufficient proportion of patients or subgroup of patients to meet the company's predefined threshold for advancement.Tebapivat was well tolerated across all dose levels, with no new safety signals identified.Agios said tebapivat is also being evaluated in a Phase 2 trial for the treatment of sickle cell disease, with top-line data ant","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AGIO":"Agios Pharmaceuticals, Inc.","BK4139":"生物科技"},"translate_title":"Agios Pharma不会推进替巴匹伐治疗低风险骨髓增生异常综合征","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AGIO":0.9},"content_text":"By Chris Wack \n\n\n \n\n\n  Agios Pharmaceuticals said it won't advance its tebapivat, an oral pyruvate kinase activator, in lower-risk myelodysplastic syndromes, after a Phase 2b trial didn't meet the company's predefined threshold to support further development in this indication. \n\n\n  The commercial-stage biopharmaceutical company said the 24-week dose-finding trial evaluated once-daily tebapivat in 65 patients with LR-MDS and anemia. \n\n\n  The primary endpoint was transfusion independence, defined as eight consecutive weeks without a transfusion during the 24-week treatment period. Agios said tebapivat demonstrated evidence of biological activity, but that it didn't see clinical benefit in a sufficient proportion of patients or subgroup of patients to meet the company's predefined threshold for advancement. \n\n\n  Tebapivat was well tolerated across all dose levels, with no new safety signals identified. \n\n\n  Agios said tebapivat is also being evaluated in a Phase 2 trial for the treatment of sickle cell disease, with top-line data anticipated in the second half of 2026. \n\n\n  Shares were down 5.5% to $28.75 in premarket trading. \n\n\n \n\n\n  Write to Chris Wack at chris.wack@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 29, 2026 07:30 ET (11:30 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2639242486","isCrawlerRequest":true}